DOYLESTOWN, PA. - May 22, 2007 - The Quigley Corporation (Nasdaq: - QGLY),
www.Quigleyco.com, originator of the zinc cold product category, announced
today the introduction of two new consumer products, extending their reach in
the over-the-counter consumer products market. Organix™ Cough and Sore
Throat Drops and Cold-EEZE Immune Support Complex-10 (ISC-10) join Cold-EEZE
Cold Remedy Lozenges and provide consumers with 2 new options to support their
health during the upcoming Cold and Flu Season. Both products are scheduled for
shipping this July. Interactive media, radio, print and trial generation
marketing initiatives will support the introductions.
Organix Cough and Sore Throat Drops are great tasting medicated drops designed
to suppress coughs, cool nasal passages and soothe irritated sore throats. This
proprietary product is manufactured in Quigley's certified organic
manufacturing facility. It is the first facility of its kind to obtain USDA
organic certification.
"Organix is a significant innovation in cough drops," said Albert
Piechotta, Director of Communications, The Quigley Corporation. "It has
the potential to generate growth by leveraging consumer's affinity for organic
products, which has grown to 66% of US consumers according to a leading
published market research report."
The Quigley Corporation is also introducing COLD-EEZE Immune Support
Complex-10, which will compete in the growing immune boosting dietary
supplement marketplace. The product features a proprietary blend of 10
important immune supporting nutrients, minerals and herbs shown to support
proper immune system functioning.
"This product will appeal to the consumer marketplace because it provides
immune support for daily and occasional use," added Piechotta.
"ISC-10 keeps your immune system working at its peak."
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a
diversified natural health medical science company. Its Cold Remedy segment is
a leading marketer and manufacturer of the COLD-EEZE® family of lozenges,
gums and sugar free tablets clinically proven to cut the common cold nearly in
half. COLD-EEZE customers include leading national wholesalers and
distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies. The Quigley Corporation has four (4) wholly owned
subsidiaries. Darius International markets health and wellness products through
its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc.
consists of two FDA approved facilities to manufacture COLD-EEZE® lozenges
as well as fulfill other contract manufacturing opportunities. Quigley Pharma
Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other factors
that may cause the company's actual performance or achievements to be
materially different from the results, performance or achievements expressed or
implied by the forward-looking statement. Factors that impact such
forward-looking statements include, among others, changes in worldwide general
economic conditions, changes in interest rates, government regulations, and
worldwide competition.
